Zoetis Inc. (NYSE:ZTS – Get Free Report) was the recipient of some unusual options trading activity on Monday. Stock traders purchased 8,106 call options on the company. This represents an increase of approximately 300% compared to the typical daily volume of 2,027 call options.
Zoetis Stock Down 3.4 %
ZTS stock opened at $144.09 on Wednesday. The business has a 50 day moving average of $164.18 and a 200 day moving average of $172.41. The firm has a market cap of $64.52 billion, a PE ratio of 26.34, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92. Zoetis has a twelve month low of $142.39 and a twelve month high of $200.33. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.
Zoetis (NYSE:ZTS – Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, research analysts forecast that Zoetis will post 6.07 EPS for the current fiscal year.
Zoetis Announces Dividend
Insider Buying and Selling at Zoetis
In related news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at $2,682,770. This trade represents a 2.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now directly owns 11,245 shares of the company’s stock, valued at $1,868,244.30. The trade was a 9.71 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,862 shares of company stock worth $312,254. 0.16% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Zoetis
Several institutional investors and hedge funds have recently made changes to their positions in ZTS. Atlantic Edge Private Wealth Management LLC boosted its stake in Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 140 shares during the last quarter. Rakuten Securities Inc. boosted its position in shares of Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 166 shares during the last quarter. Navigoe LLC bought a new stake in Zoetis in the 4th quarter worth about $30,000. Dunhill Financial LLC raised its position in Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after buying an additional 75 shares during the last quarter. Finally, Murphy & Mullick Capital Management Corp bought a new position in Zoetis during the 4th quarter valued at about $44,000. Institutional investors own 92.80% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on ZTS. Piper Sandler boosted their price objective on shares of Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. Barclays boosted their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Morgan Stanley lowered their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Stifel Nicolaus reduced their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $215.90.
Get Our Latest Report on Zoetis
About Zoetis
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Read More
- Five stocks we like better than Zoetis
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Tariff-Proof Stocks: 3 Big Bargains With Huge Upside Potential
- What is a SEC Filing?
- Qualcomm Breaks Down But RSI Signals It’s Severely Oversold
- How is Compound Interest Calculated?
- Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.